👀Lunes 16 de noviembre a las 16:00h: nueva cita en un webinar 🖥️ para revisión de las novedades en carcinoma de nasofaringe. Información y registro en ttccgrupo.com
Time trends of human papillomavirus-attributable head and neck cancers: the BROADEN study academic.oup.com/jnci/articl…
44
TTCC-GrupoTratamiento Tumores Cabeza y Cuello retweeted
👀Nueva edición 👀Curso de Formación Conjunta en Tumores de Cabeza y Cuello. 🖥️On line hasta el 15 de diciembre. Clausura en formato Comité de Tumores presencial en el III Congreso FETTCC en enero, Madrid. 📌fundacionttcc.com @ttccgroup @_SEOM @SEORLCCC @SECOMmxf @SEOR_ESP
FDA Approves Dual-Targeted Therapy for Head and Neck Cancer medpagetoday.com/hematologyo…
Treatment of Stage IB to III Nasopharyngeal Carcinoma: CSCO-ASCO Guideline Update | Journal of Clinical Oncology ascopubs.org/doi/abs/10.1200…
Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline | Journal of Clinical Oncology ascopubs.org/doi/abs/10.1200…
TTCC-GrupoTratamiento Tumores Cabeza y Cuello retweeted
Days after #ESMO26
FAN-TAS-TIC good news
@Genmab $GMAB has announced that Petosentamab, a bispecific anti EGFRxLGR5 plus pembro meets both primary endpoints possibly becoming the new 1st line in R/M PDL1+ HNSCC
✅ OS . OS: HR 0.50 (95% CI, 0.37, 0.67); p<0.0001
✅ ORR. 3.17 (95% CI, 2.06, 4.89; p<0.0001)
⬇️ 50% risk of death
I foresee reliable efficacy only in HPV negative. Let see full results next meetings
#Oncology @OncoAlert @brunolarvol
@myESMO @ASCO
Today, we announced positive Phase 3 topline results for our investigational therapy in head and neck cancer. The findings reinforce the potential of our differentiated antibody science and reflect our continued commitment to developing transformative medicines for people living with cancer.
Learn more: gmab.ly/2eLa5100ARh.
TTCC-GrupoTratamiento Tumores Cabeza y Cuello retweeted
#HNSCC #ESMO26
RADIAN-TTCC Dostarlimab and niraparib in the CRT soace in LA PD-L1+ disease
An stunning effort from Dr Oliva, rest investigators and the spanish cooperative group @ttccgroup
@myESMO @OncoAlert @brunolarvol
@FundacionTTCC
⚕️XVII Curso de Formación Conjunta en Tumores de Cabeza y Cuello. Inscripción Abierta. Sólo xa profesionales sanitarios. Aval Científico de #SECOMmxf et al, vía @FundacionTTCC
🍀cursoformacionconjunta.funda…
🗓️De 15 Noviembre a 15 Diciembre 2026💻On-line
A randomized, placebo-controlled, phase II study of docetaxel and platinum with or without erlotinib in recurrent/metastatic head and neck squamous-cell carcinomas - ESMO Open esmoopen.com/article/S2059-7…
TTCC-GrupoTratamiento Tumores Cabeza y Cuello retweeted
No good news for the @BioNTech_Group mRNA HPV vaccine in 1st L R/M #HNSCC in the latest interim analysis
🔴 Negative PFS
⏱️Awaiting results for Overall Survival in next analyses (coprimary endpoint)
@OncoAlert @brunolarvol @OncBrothers
Neoadjuvant PIK3CA Inhibition With Alpelisib in Head and Neck Squamous Cell Cancer: A Window-of-Opportunity Trial and Biomarker Study | JCO Oncology Advances ascopubs.org/doi/full/10.120…
PDS0101 With Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma jamanetwork.com/journals/jam…
Zanzalintinib With Pembrolizumab and Cetuximab in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck | JCO Oncology Advances ascopubs.org/doi/full/10.120…
TTCC-GrupoTratamiento Tumores Cabeza y Cuello retweeted
Abierto el plazo de envío de comunicaciones y casos clínicos para el III Congreso de la Fundación Española de Tumores de Cabeza y Cuello: 28 y 29 de enero en Madrid. Toda la información en fundacionttcc.com
@ttccgroup
@_SEOM
@SEORLCCC
@SECOMmxf
@SEOR_ESP
TTCC-GrupoTratamiento Tumores Cabeza y Cuello retweeted
Happy to see our comment in @TheLancet about #NIVOPOSTOP trial
After reading the full manuscript, some points demand attention
🪫Lost of statistical significance with the blinded vs investigator review
⬆️% Baseline post-op locoregional disease
@OncoAlert @brunolarvol
Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma | Journal of Clinical Oncology ascopubs.org/doi/abs/10.1200…
Darolutamide Alone and in Combination With Goserelin in Androgen Receptor–Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
Advances in Systemic Therapies for Rare Head and Neck Malignancies: Spotlight on Adenoid Cystic Carcinoma, Differentiated Thyroid Cancer, and Sinonasal/Paranasal Tumors | American Society of Clinical Oncology Educational Book ascopubs.org/doi/10.1200/EDB…
















